The impact of short daily and nocturnal hemodialysis on quality of life, cardiovascular risk and survival

Journal of Nephrology

Volumn 24, Issue 4, 2011, Pages 405-415

  Culleton, Bruce F ^a   Asola, Markku R ^b  

^a BAXTER HEALTHCARE CORPORATION   (United States)

^b Baxter International Inc   (Sweden)

Author keywords

Cardiovascular; Home hemodialysis; Left ventricular hypertrophy; Nocturnal hemodialysis; Quality of life; Short daily hemodialysis

Indexed keywords

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CONGESTIVE HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MINERAL METABOLISM; MORTALITY; NOCTURNAL HEMODIALYSIS; PERIPHERAL VASCULAR DISEASE; QUALITY OF LIFE; SHORT DAILY HEMODIALYSIS; SUDDEN DEATH; SURVIVAL; TREATMENT DURATION;

CARDIOVASCULAR DISEASES; HEMODIALYSIS, HOME; HUMANS; KIDNEY FAILURE, CHRONIC; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 79960287299     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2011.8422     Document Type: Article

References (70)

1. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant. 2005;20:2587-2593.
2. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(Suppl):S16-S23.
3. London GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial. 2003;16:85-94.
4. McIntyre CW. Haemodialysis-induced myocardial stunning in chronic kidney disease: a new aspect of cardiovascular disease. Blood Purif. 2010;29:105-110.
5. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186-192.
6. Zoccali C, Benedetto FA, Mallamaci F, et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int. 2004;65:1492-1498.
7. London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001;12:2759-2767.
8. Blagg CR. Home haemodialysis: 'home, home, sweet, sweet home!' Nephrology (Carlton). 2005;10:206-214.
9. Scribner BH, Cole JJ, Ahmad S, Blagg CR. Why thrice weekly dialysis? Hemodial Int. 2004;8:188-192.
10. Kramer A, Stel V, Zoccali C, et al; ERA-EDTA Registry. An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. Nephrol Dial Transplant. 2009;24:3557-3566.
11. US Renal Data System. Morbidity and mortality. Annual data report. Available from: http://www.usrds.org/2009/pdf/V1_05_09.PDF. Accessed February 24, 2011.
12. Lameire N, Van Biesen W, Vanholder R. Did 20 years of technological innovations in hemodialysis contribute to better patient outcomes? Clin J Am Soc Nephrol. 2009;4(Suppl 1):S30-S40.
13. Evans RW, Manninen DL, Garrison LP Jr, et al. The quality of life of patients with end-stage renal disease. N Engl J Med. 1985;312:553-559.
14. Mapes DL, Lopes AA, Satayathum S, et al. Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int. 2003;64:339-349.
15. Chan CT. Cardiovascular effects of home intensive hemodialysis. Adv Chronic Kidney Dis. 2009;16:173-178.
16. Mapes DL, Bragg-Gresham JL, Bommer J, et al. Healthrelated quality of life in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44(Suppl 2):54-60.
17. Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med. 1981;305:1176-1181.
18. Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int. 1985;28:526-534.
19. Chertow GM, Kurella M, Lowrie EG. The tortoise and hare on hemodialysis: does slow and steady win the race? Kidney Int. 2006;70:24-25.
20. Eknoyan G, Beck GJ, Cheung AK, et al; Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010-2019.
21. Locatelli F, Martin-Malo A, Hannedouche T, et al; Membrane Permeability Outcome (MPO) Study Group. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol. 2009;20:645-654.
22. Eloot S, van Biesen W, Dhondt A, et al. Impact of increasing haemodialysis frequency versus haemodialysis duration on removal of urea and guanidino compounds: a kinetic analysis. Nephrol Dial Transplant. 2009;24:2225-2232. doi:10.1093/ndt/gfp059.
23. Traeger J, Galland R, Delawari E, Arkouche W, Hadden R. Six years' experience with short daily hemodialysis: do the early improvements persist in the mid and long term? Hemodial Int. 2004;8:151-158. doi:10.1111/j.1492-7535.2004.01089.x.
24. Williams AW, Chebrolu SB, Ing TS, et al; Daily Hemodialysis Study Group. Early clinical, quality-of-life, and biochemical changes of "daily hemodialysis" (6 dialyses per week). Am J Kidney Dis. 2004;43:90-102.
25. Eloot S, Van Biesen W, Dhondt A, et al. Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney Int. 2008;73:765-770.
26. Raj DS, Ouwendyk M, Francoeur R, Pierratos A. Beta(2)-Microglobulin kinetics in nocturnal haemodialysis. Nephrol Dial Transplant. 2000;15:58-64.
27. Arneson TJ, Liu J, Qiu Y, Gilbertson DT, Foley RN, Collins AJ. Hospital treatment for fluid overload in the Medicare hemodialysis population. Clin J Am Soc Nephrol. 2010;5:1054-1063.
28. Kalantar-Zadeh K, Regidor DL, Kovesdy CP, et al. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation. 2009;119:671-679.
29. Flythe JE, Kimmel SE, Brunelli SM. Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney Int. 2011;79:250-257.
30. Bame SI, Petersen N, Wray NP. Variation in hemodialysis patient compliance according to demographic characteristics. Soc Sci Med. 1993;37:1035-1043.
31. Sharp J, Wild MR, Gumley AI, Deighan CJ. A cognitive behavioral group approach to enhance adherence to hemodi alysis fluid restrictions: a randomized controlled trial. Am J Kidney Dis. 2005;45:1046-1057.
32. Suri RS, Nesrallah GE, Mainra R, et al. Daily hemodialysis: a systematic review. Clin J Am Soc Nephrol. 2006;1:33-42.
33. Lindsay RM, Leitch R, Heidenheim AP, Kortas C; London Daily/Nocturnal Hemodialysis Study. The London Daily/ Nocturnal Hemodialysis Study: study design, morbidity, and mortality results. Am J Kidney Dis. 2003;42(Suppl):5-12.
34. Ting GO, Kjellstrand C, Freitas T, Carrie BJ, Zarghamee S. Long-term study of high-comorbidity ESRD patients converted from conventional to short daily hemodialysis. Am J Kidney Dis. 2003;42:1020-1035.
35. Woods JD, Port FK, Orzol S, et al. Clinical and biochemical correlates of starting "daily" hemodialysis. Kidney Int. 1999;55:2467-2476.
36. Quintaliani G, Buoncristiani U, Fagugli R, et al. Survival of vascular access during daily and three times a week hemodialysis. Clin Nephrol. 2000;53:372-377.
37. Johansen KL, Zhang R, Huang Y, et al. Survival and hospitalization among patients using nocturnal and short daily compared to conventional hemodialysis: a USRDS study. Kidney Int. 2009;76:984-990.
38. Kjellstrand CM, Buoncristiani U, Ting G, et al. Short daily haemodialysis: survival in 415 patients treated for 1006 patient-years. Nephrol Dial Transplant. 2008;23:3283-3289.
39. Chertow GM, Levin NW, Beck GJ, et al; FHN Trial Group. In-center hemodialysis six times per week versus three times per week. N Engl J Med. 2010;363:2287-2300.
40. Foley RN, Herzog CA, Collins AJ; United States Renal Data System. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int. 2002;62:1784-1790.
41. Tozawa M, Iseki K, Iseki C, Takishita S. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int. 2002;61:717-726.
42. Fagugli RM, Reboldi G, Quintaliani G, et al. Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis. 2001;38:371-376.
43. Goldfarb-Rumyantzev AS, Leypoldt JK, Nelson N, Kutner NG, Cheung AK. A crossover study of short daily haemodialysis. Nephrol Dial Transplant. 2006;21:166-175. doi:10.1093/ ndt/gfi116.
44. Koshikawa S, Akizawa T, Saito A, Kurokawa K. Clinical effect of short daily in-center hemodialysis. Nephron Clin Pract. 2003;95:c23-c30. doi:10.1159/000073015.
45. Okada K, Abe M, Hagi C, et al. Prolonged protective effect of short daily hemodialysis against dialysis-induced hypotension. Kidney Blood Press Res. 2005;28:68-76. doi:10.1159/000083586.
46. Reynolds JT, Homel P, Cantey L, et al. A one-year trial of incenter daily hemodialysis with an emphasis on quality of life. Blood Purif. 2004;22:320-328. doi:10.1159/000079186.
47. Suri RS, Garg AX, Chertow GM, et al; Frequent Hemodialysis Network Trial Group. Frequent Hemodialysis Network (FHN) randomized trials: study design. Kidney Int. 2007;71:349-359. doi:10.1038/sj.ki.5002032.
48. Bugeja A, Dacouris N, Thomas A, et al. In-center nocturnal hemodialysis: another option in the management of chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:778-783. doi:10.2215/CJN.05221008.
49. David S, Kümpers P, Eisenbach GM, Haller H, Kielstein JT. Prospective evaluation of an in-centre conversion from conventional haemodialysis to an intensified nocturnal strategy. Nephrol Dial Transplant. 2009;24:2232-2240. doi:10.1093/ ndt/gfp029.
50. Walsh M, Culleton B, Tonelli M, Manns B. A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int. 2005;67:1500-1508. doi:10.1111/j.1523-1755.2005.00228.x.
51. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int. 2002;61:2235-2239. doi:10.1046/j.1523-1755.2002.00362.x.
52. Nesrallah G, Suri R, Moist L, Kortas C, Lindsay RM. Volume control and blood pressure management in patients undergoing quotidian hemodialysis. Am J Kidney Dis. 2003;42(Suppl):13-17. doi:10.1016/S0272-6386(03)00532-8.
53. Chan CT, Harvey PJ, Picton P, Pierratos A, Miller JA, Floras JS. Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension. 2003;42:925-931. doi:10.1161/01.HYP.0000097605.35343.64.
54. Bergman A, Fenton SS, Richardson RM, Chan CT. Reduction in cardiovascular related hospitalization with nocturnal home hemodialysis. Clin Nephrol. 2008;69:33-39.
55. Pauly RP, Gill JS, Rose CL, et al. Survival among nocturnal home haemodialysis patients compared to kidney transplant recipients. Nephrol Dial Transplant. 2009;24:2915-2919. doi:10.1093/ndt/gfp295.
56. Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA. 2007;298:1291-1299.
57. Lockridge RS Jr, Spencer M, Craft V, et al. Nightly home hemodialysis: five and one-half years of experience in Lynchburg, Virginia. Hemodial Int. 2004;8:61-69.
58. Rao M, Muirhead N, Klarenbach S, Moist L, Lindsay RM. Management of anemia with quotidian hemodialysis. Am J Kidney Dis. 2003;42(Suppl):18-23.
59. Schwartz DI, Pierratos A, Richardson RM, Fenton SS, Chan CT. Impact of nocturnal home hemodialysis on anemia management in patients with end-stage renal disease. Clin Nephrol. 2005;63:202-208.
60. Rocco MV, Kliger AS, and the FHN Trial Group. Effects of Nocturnal Home Hemodialysis: The Frequent Hemodialysis Network (FHN) Nocturnal Trial [abstract]. ASN Online. 2010. Abstract LB-FC1. Available at: http://www.asn-online.org/education_and_meetings/kidneyweek/2010/LBCT_JASN_final.pdf. Access April 8, 2011.
61. Rocco MV, Larive B, Eggers PW, et al; FHN Trial Group. Baseline characteristics of participants in the Frequent Hemodialysis Network (FHN) daily and nocturnal trials. Am J Kidney Dis. 2011;57:90-100.
62. Komenda P, Garfield S, White Poret A, Sood MM, Gavaghan MB. A costing model for use in evaluating the fiscal impact of home versus in-center dialysis within various healthcare systems [abstract]. ASN Online. 2010. Abstract TH-FC124. Available at: http://www.asn-online.org/press/RW10/2c-Komenda%20Abstract.pdf. Accessed April 8, 2011.
63. Cameron JI, Whiteside C, Katz J, Devins GM. Differences in quality of life across renal replacement therapies: a metaanalytic comparison. Am J Kidney Dis. 2000;35:629-637.
64. Heidenheim AP, Muirhead N, Moist L, Lindsay RM. Patient quality of life on quotidian hemodialysis. Am J Kidney Dis. 2003;42(Suppl):36-41.
65. Visaya MA. Hemodialysis patients' perceptions of home hemodialysis and self-care. CANNT J. 2010;20:23-28.
66. Zhang AH, Bargman JM, Lok CE, et al. Dialysis modality choices among chronic kidney disease patients: identifying the gaps to support patients on home-based therapies. Int Urol Nephrol. 2010;42:759-764.
67. Pipkin M, Eggers PW, Larive B, et al; Frequent Hemodialysis Network Trial Group. Recruitment and training for home hemodialysis: experience and lessons from the Nocturnal Dialysis Trial. Clin J Am Soc Nephrol. 2010;5:1614-1620.
68. Wise M, Schatell D, Klicko K, Burdan A, Showers M. Successful daily home hemodialysis patient-care partner dyads: benefits outweigh burdens. Hemodial Int. 2010;14:278-288.
69. Rioux JP, Faratro R, Chan CT. Nocturnal home hemodialysis: implementation, quality assurance and future challenges. Minerva Urol Nefrol. 2010;62:103-110.
70. Pierratos A, Ouwendyk M, Francoeur R, et al. Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol. 1998;9:859-868.